Coley halts work on hepatitis drug | Chemical & Engineering News
Volume 85 Issue 5 | p. 24 | Concentrates
Issue Date: January 29, 2007

Coley halts work on hepatitis drug

Department: Business

Massachusetts-based Coley Pharmaceutical will discontinue development of Actilon, its candidate for the treatment of hepatitis C virus infection, due to disappointing results from two concurrent clinical trials. In dropping the program, Coley says it has reduced its workforce, primarily drug development staff, by approximately 22%, or 33 employees, and that it will seek to outsource drug development activities going forward.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment